{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:34:01Z","timestamp":1770960841202,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.clon.2019.11.010","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T08:57:48Z","timestamp":1576227468000},"page":"e145-e153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"N.","family":"Reed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Glen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gerrard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.R.","family":"Lyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Strachan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wadsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Newbold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2019.11.010_bib2","first-page":"129","article-title":"Multi-kinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib","volume":"8","author":"Stjepanovic","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.clon.2019.11.010_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2019.11.010_bib4","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the Phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2019.11.010_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/mco.2017.1265","article-title":"Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer","volume":"7","author":"Suyama","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clon.2019.11.010_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","article-title":"Incidence and timing of common adverse events in lenvatinib-treated patients from the SELECT trial and their association with survival outcomes","volume":"56","author":"Haddad","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.clon.2019.11.010_bib7","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1517\/14740338.2015.1102883","article-title":"Drug safety evaluation of lenvatinib for thyroid cancer","volume":"14","author":"Krajewska","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clon.2019.11.010_bib8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00228-017-2299-y","article-title":"Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials","volume":"73","author":"Li","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clon.2019.11.010_bib9","doi-asserted-by":"crossref","first-page":"44545","DOI":"10.18632\/oncotarget.10019","article-title":"Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis","volume":"7","author":"Zhu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clon.2019.11.010_bib10","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2017.0205","article-title":"Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice","author":"Berdelou","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2019.11.010_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.atherosclerosis.2017.03.039","article-title":"Lenvatinib, an oral multi-kinase inhibitor, -associated hypertension: potential role of vascular endothelial dysfunction","volume":"260","author":"Sueta","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clon.2019.11.010_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/ijms18030625","article-title":"The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors","volume":"18","author":"Ancker","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"Suppl 4","key":"10.1016\/j.clon.2019.11.010_bib13","first-page":"iv353","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"25","author":"Wirth","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2019.11.010_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/SPC.0b013e32835ec861","article-title":"Mechanisms of TKI-induced diarrhea in cancer patients","volume":"7","author":"Bowen","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.clon.2019.11.010_bib15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/0284186X.2015.1119883","article-title":"Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: is the cause in the mucosa?","volume":"55","author":"Boers-Sonderen","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2019.11.010_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.clon.2019.11.010_bib17","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-5050","article-title":"Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor","volume":"14","author":"Steeghs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2019.11.010_bib18","article-title":"Hypertension in adults: diagnosis and management","year":"2016","journal-title":"Clin Guidel [CG127]"},{"key":"10.1016\/j.clon.2019.11.010_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","article-title":"British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary","volume":"328","author":"Williams","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.clon.2019.11.010_bib20","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2019.11.010_bib21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clgc.2016.12.016","article-title":"Angiotensin inhibitors as treatment of sunitinib\/pazopanib-induced hypertension in metastatic renal cell carcinoma","volume":"15","author":"Penttila","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clon.2019.11.010_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S002966511500419X","article-title":"Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later","volume":"75","author":"Ryan","year":"2016","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.clon.2019.11.010_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1615\/CritRevOncog.v17.i3.90","article-title":"Cancer cachexia: from molecular mechanisms to patient\u2019s care","volume":"17","author":"Lucia","year":"2012","journal-title":"Crit Rev Oncol"},{"key":"10.1016\/j.clon.2019.11.010_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pmr.2016.08.004","article-title":"Cancer-related fatigue: persistent, pervasive, and problematic","volume":"28","author":"Gerber","year":"2017","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.clon.2019.11.010_bib25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bjsports-2016-096422","article-title":"Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis","volume":"52","author":"Hilfiker","year":"2018","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.clon.2019.11.010_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","article-title":"Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis","volume":"3","author":"Mustian","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2019.11.010_bib27","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","article-title":"Incidence and implications of chemotherapy related hand-foot syndrome","volume":"15","author":"Nikolau","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clon.2019.11.010_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CAD.0b013e3283161012","article-title":"Hypertension and proteinuria: a class-effect of antiangiogenic therapies","volume":"20","author":"Launay-Vacher","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clon.2019.11.010_bib29","article-title":"Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clon.2019.11.010_bib30","article-title":"Cardio-oncology: a new sub-specialty","author":"Bennett","year":"2018","journal-title":"Br J Cardiol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519304984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655519304984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:47:41Z","timestamp":1760543261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655519304984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0936655519304984"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2019.11.010","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2019.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}